Revised forecast
Fiscal year ending December 2026 · Full yearPrevious forecast published 13 February 2026The bar length represents the relative magnitude of change, based on the item that changed the most in this document.
The revision reflects the recognition of ¥15,780 million as revenue for the US$100 million upfront contract payment under the exclusive licensing agreement with AbbVie for an EP4 agonist program, using an assumed exchange rate of US$1 = ¥157.8.
| Item | Details |
|---|---|
| Net Sales | 33,800～48,800 → ¥48,800 million |
| Operating profit | 700～15,700 → ¥15,700 million |
| Fiscal Period Covered | Fiscal year ending December 2026 |
| Period Covered | Full year |
| Publication date of previous forecast | 13 February 2026 |
| Previous-period results | Revenue of ¥29,615 million, core operating loss of ¥352 million and operating loss of ¥8,462 million (fiscal year ended December 2025) |
| Reason for the revision | The revision reflects the recognition of ¥15,780 million as revenue for the US$100 million upfront contract payment under the exclusive licensing agreement with AbbVie for an EP4 agonist program, using an assumed exchange rate of US$1 = ¥157.8. |
| Consolidated / non-consolidated | Consolidated |
Items this document does not state (5)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The subsidiary entered into an exclusive licensing agreement with AbbVie for an EP4 agonist program and will receive an upfront contract payment of US$100 million. The ¥15,780 million upfront payment has been reflected in revenue based on the assumptions that the agreement will be completed by 31 December 2026, the accounting treatment will be agreed with the accounting auditor, and the assumed exchange rate will be US$1 = ¥157.8.